The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy

British Journal of Pharmacology

Volumn 151, Issue 7, 2007, Pages 1117-1128

  Wallace, V C J ^a   Segerdahl, A R ^a   Lambert, D M ^b   Vandevoorde, S ^b   Blackbeard, J ^a   Pheby, T ^a   Hasnie, F ^a   Rice, A S C ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cannabinoids; FAAH; Neuropathic pain; Open field activity; Palmitoylallylamide; Palmitoylethanolamide

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANALGESIC AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FATTY ACID AMIDASE; GABAPENTIN; L 29; PALMIDROL; PALMITOYLALLYLAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PSYCHOTROPIC AGENT; RIMONABANT; UNCLASSIFIED DRUG; ZALCITABINE;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HYPERSENSITIVITY; IN VIVO STUDY; LOCOMOTION; MALE; MECHANICAL STIMULATION; NERVE INJURY; NEUROPATHY; NONHUMAN; OPEN FIELD BEHAVIOR; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; SCIATIC NERVE; THERMAL STIMULATION; VARICELLA ZOSTER VIRUS;

AMIDES; AMINES; ANIMALS; BEHAVIOR, ANIMAL; BORNANES; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAMMA-AMINOBUTYRIC ACID; HINDLIMB; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PALMITIC ACIDS; PHYSICAL STIMULATION; PIPERIDINES; PPAR ALPHA; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SCIATIC NEUROPATHY; TEMPERATURE; ZALCITABINE;

EID: 34547566970     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707326     Document Type: Article

References (88)

1. Abdi S, Lee DH, Chung JM (1998). The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 87: 1360-1366.
2. Ahmad KS, Rice ASC (1999). Von Frey hairs compared with a force transducer for sensory measurement in normal and neuropathic rats. Poster Presentation at The Society for Neuroscience Annual Meeting Miami, FL.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300-302.
4. Barann M, Moldering SG, Bruss M, Bonisch H, Urban BW, Gothert M (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137: 589-596.
5. Ben Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z et al. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 23-31.
6. Bridges D, Ahmad K, Rice ASC (2001). The synthetic cannabinoid WIN55, 212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133: 586-594.
7. Calignano A, La RanA G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
8. Calignano A, La Rana G, Piomelli D (2001). Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419: 191-198.
9. Carli M, Prontera C, Samanin R (1989). Effect of 5-HT1A agonists on stress-induced deficit in open field locomotor activity of rats: evidence that this model identifies anxiolytic-like activity. Neuropharmacology 28: 471-476.
10. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148: 102-113.
11. Childers SR, Sexton T, Roy MB (1994). Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47: 711-715.
12. Collino M, Aragno M, Mastrocola R, Benetti E, Gallicchio M, Dianzani C et al. (2006). Oxidative stress and inflammatory response evoked by transient cerebral ischemia/reperfusion: effects of the PPAR-alpha agonist WY14643. Free Radic Biol Med 41: 579-589.
13. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G (2002). Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol 135: 181-187.
14. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR et al. (2001). Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 98: 9371-9376.
15. Cryan JF, Holmes A (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790.
16. Dalziel RG, Bingham S, Sutton D, Grant D, Champion JM, Dennis SA et al. (2004). Allodynia in rats infected with varicella zoster virus - a small animal model for post-herpetic neuralgia. Brain Res Brain Res Rev 46: 234-242.
17. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R et al. (2005). Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163.
18. De Lago E, Petrosino S, Valenti M, Morera E, Ortega-Gutierrez S, Fernandez-Ruiz J et al. (2005). Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol 70: 446-452.
19. De Vry J, Kuhl E, Franken-Kunkel P, Eckel G (2004). Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur J Pharmacol 491: 137-148.
20. Donovan-Rodriguez T, Dickenson AH, Urch CE (2005). Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology 102: 132-140.
21. Dworkin RH, Gitlin MJ (1991). Clinical aspects of depression in chronic pain patients. Clin J Pain 7: 79-94.
22. Fan P (1995). Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol 73: 907-910.
23. Farquhar-Smith WP, Jaggar SI, Rice ASC (2002). Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain 97: 11-21.
24. Farquhar-Smith WP, Rice ASC (2001). Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology 94: 507-513.
25. Farquhar-Smith WP, Rice ASC (2003). A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99: 1391-1401.
26. Finnerup NB, Otto M, McQua YHJ, Jensen TS, Sindrup SH (2005). Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 118: 289-305.
27. Fleetwood-Walker SM, Quinn JP, Wallace C, Blackburn-Munro G, Kelly BG, Fiskerstrand CE et al. (1999). Behavioural changes in the rat following infection with varicella-zoster virus. J Genet Virol 80: 2433-2436.
28. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L et al. (2001). The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
29. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ et al. (2005). Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain 118: 97-111.
30. Giang DK, Cravat TBF (1997). Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 94: 2238-2242.
31. Griffin G, Wray EJ, Tao Q, McAllister SD, Rorrer WK, Aung MM et al. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur J Pharmacol 377: 117-125.
32. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, GraY AT, Hansen BM et al. (1998). Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70: 671-676.
33. Hargreaves K, Dubner R, Brown FFC, Jovis J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
34. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I et al. (2007). Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience 144: 1495-1508.
35. Helyes Z, Nemeth J, Than M, Bolcskei K, Pinter E, SzolcsanyI J (2003). Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat. Life Sci 73: 2345-2353.
36. Hempenstall K, Nurmikko TJ, Johnson RW, A'hern RP, Rice ASC (2005). Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2: e164.
37. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997). The analgesic effects of R(+)-Win 55212′2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. pp. Neurosci Letts 221: 157-160.
38. Hohmann AG (2007). Inhibitors of monoacylglycerol lipase as novel analgesics. Br J Pharmacol 150: 673-675.
39. Hohmann A, Suplita R (2006). Endocannabinoid mechanisms of pain modulation. AAPS J 8: E693-E708.
40. Holmes A (2001). Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev 25: 261-273.
41. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
42. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296: 420-425.
43. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC (1998). The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76: 189-199.
44. Jarbe TU, Dipatrizio NV, Lu D, Makriyannis A (2004). Adamantyl-delta8- tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats. Behav Pharmacol 15: 517-521.
45. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288.
46. Jhaveri MD, RichardsoN D, Kendall DA, Barrett DA, Chapman V (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 26: 13318-13327.
47. Joseph EK, Chen X, Khasar SG, Levine JD (2004). Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 107: 147-158.
48. Kehl LJ, Hamamoto DT, Wacnik PW, Croft DL, Norsted BD, Wilcox GL et al. (2003). A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103: 175-186.
49. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM et al. (2001). Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J 356: 899-906.
50. Lambert DM, Di Marzo V (1999). The palmitoylethanolamide and oleamide enigmas : are these two fatty acid amides cannabimimetic? Curr Med Chem 6: 757-773.
51. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ (2002). The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9: 663-674.
52. Leung D, Du W, Hardouin C, Cheng H, Hwang I, Cravatt BF et al. (2005). Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg Med Chem Lett 15: 1423-1428.
53. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL et al. (2004a). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448.
54. Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004b). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327.
55. LoVerme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A et al. (2005a). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
56. LoVerme J, LA Rana G, Russo R, Calignano A, Piomelli D (2005b). The search for the palmitoylethanolamide receptor. Life Sci 77: 1685-1698.
57. LoVerme J, Russo R, La Rana G, Fu J, Farthing J, Mattace-Raso G et al. (2006). Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther 319: 1051-1061.
58. MacKie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15: 6552-6561.
59. Maione S, Bisogno T, De NV, Palazz OE, Cristino L, Valenti M et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 316: 969-982.
60. Malan Jr TP, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T et al. (2001). CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245.
61. Malan Jr TP, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F (2003). CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67.
62. Meyer-Rosberg K, Kvarnstrom A, Kinnman E, Gordh T, Nordfors LO, Kristofferson A (2001). Peripheral neuropathic pain - a multidimensional burden for patients. Eur J Pain 5: 379-389.
63. Mogil JS, Crager SE (2004). What should we be measuring in behavioral studies of chronic pain in animals? Pain 112: 12-15.
64. Moller KA, Johansson B, Berge OG (1998). Assessing mechanical allodynia in the rat paw with a new electronic algometer. J Neurosci Methods 84: 41-47.
65. Oz M, Zhang L, Morales M (2002). Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes. Synapse 46: 150-156.
66. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS et al. (2005). The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 46: 342-349.
67. Pertwee RG (2001). Cannabinoid receptors and pain. Prog Neurobiol 63: 569-611.
68. Pertwee RG, Fernando SR, Griffin G, Abadji V, Makriyannis A (1995). Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol 272: 73-78.
69. Petrosino S, Palazzo E, De NV, Bisogno T, Rossi F, Maione S et al. (2007). Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 52: 415-422.
70. Rice AS (2001). Cannabinoids and pain. Curr Opin Investig Drugs 2: 399-414.
71. Rice AS, Farquhar-Smith WP, Nagy I (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids 66: 243-256.
72. Rice ASC (2005). Cannabinoids. In: Melzack and Wall: Textbook of Pain. Elsevier: London, pp 521-540.
73. Rice ASC, Lever I, Zarnegar R (2007). Cannabinoids and Analgesia, with Special Reference to Neuropathic Pain In: McQuay HJ and Moore RA (eds). IASP Press: Seattle, (in press).
74. Richardson JD, Kilo S, Hargreaves KM (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119.
75. Roberts LA, Christie MJ, Connor M (2002). Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 137: 421-428.
76. Scott DA, Wright CE, Angus JA (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109: 124-131.
77. Seltzer Z, Dubner R, Shir Y (1990). A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
78. Smith FL, Fujimori K, Lowe J, Welch SP (1998). Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 60: 183-191.
79. Smith GD, Harrison SM, Birch PJ, Elliot PJ, Malcangio M, Bowery NG (1994). Increased sensitivity to the antinociceptive activity of (+/-)- baclofen in an animal model of chronic neuropathic, but not chronic inflammatory hyperalgesia. Neuropharmacology 33: 1103-1108.
80. Tsuboi K, Sun YX, Okamoto Y, Araki N, Tonai T, Ueda N (2005). Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280: 11082-11092.
81. Twitchell W, Brown S, Mackie K (1997). Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 78: 43-50.
82. Vandevoorde S, Jonsson KO, Fowler CJ, Lambert DM (2003a). Modifications of the ethanolamine head in N-palmitoylethanolamine: synthesis and evaluation of new agents interfering with the metabolism of anandamide. J Med Chem 46: 1440-1448.
83. Vandevoorde S, Lambert DM, Smart D, Jonsson KO, Fowler CJ (2003b). N-Morpholino- and N-diethyl-analogues of palmitoylethanolamide increase the sensitivity of transfected human vanilloid receptors to activation by anandamide without affecting fatty acid amidohydrolase activity. Bioorg Med Chem 11: 817-825.
84. Verri Jr WA, Molina RO, Schivo IR, Cunha TM, Parada CA, Poole S. et al. (2005). Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats. J Pharmacol Exp Ther 315: 609-615.
85. Wallace VC, Blackbeard J, Segerdahl A, Hasnie FS, Pheby T, McMahon SB et al. (2007). Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy. Pain (In press).
86. Wallace VC, Cottrell DF, Brophy PJ, Fleetwood-Walker SM (2003). Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids. J Neurosci 23: 3221-3233.
87. Wallace VC, McMahon SB, Rice ASC (2006). The Characterisation of a Rodent Model of Antiretroviral-Associated Painful Peripheral Neuropathy. Poster presentation at The Society for Neuroscience Annual Meeting, Atlanta, GA.
88. Zimmermann M (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.